{"title":"制药业的 \"潮汐 \"如何逆转","authors":"Deborah McElhone, Barrie Cassey","doi":"10.56367/oag-043-11453","DOIUrl":null,"url":null,"abstract":"\n \n Two seasoned experts from CPI, Medicines Manufacturing Innovation Centre, detail how the “tides” have turned in pharma manufacturing. Oligonucleotides and peptides are two of the fastest-growing pharmaceutical drug modalities with the potential to revolutionise the treatment of many human diseases. The incredible demand for new type II diabetes and obesity peptide therapies recently launched by Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) and the acceleration in approvals of oligonucleotide therapies make them a hot topic in the pharmaceutical world.\n","PeriodicalId":475859,"journal":{"name":"Open Access Government","volume":" 41","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How the “tides” have turned in pharma manufacturing\",\"authors\":\"Deborah McElhone, Barrie Cassey\",\"doi\":\"10.56367/oag-043-11453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n Two seasoned experts from CPI, Medicines Manufacturing Innovation Centre, detail how the “tides” have turned in pharma manufacturing. Oligonucleotides and peptides are two of the fastest-growing pharmaceutical drug modalities with the potential to revolutionise the treatment of many human diseases. The incredible demand for new type II diabetes and obesity peptide therapies recently launched by Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) and the acceleration in approvals of oligonucleotide therapies make them a hot topic in the pharmaceutical world.\\n\",\"PeriodicalId\":475859,\"journal\":{\"name\":\"Open Access Government\",\"volume\":\" 41\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Access Government\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.56367/oag-043-11453\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Government","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.56367/oag-043-11453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
来自 CPI（药品制造创新中心）的两位资深专家详细介绍了制药业的 "潮汐 "是如何转向的。寡核苷酸和多肽是增长最快的两种药物模式，有可能彻底改变许多人类疾病的治疗方法。诺和诺德（semaglutide）和礼来（tirzepatide）最近推出的新型 II 型糖尿病和肥胖症多肽疗法需求量惊人，寡核苷酸疗法的审批速度也在加快，这使它们成为制药界的热门话题。
How the “tides” have turned in pharma manufacturing
Two seasoned experts from CPI, Medicines Manufacturing Innovation Centre, detail how the “tides” have turned in pharma manufacturing. Oligonucleotides and peptides are two of the fastest-growing pharmaceutical drug modalities with the potential to revolutionise the treatment of many human diseases. The incredible demand for new type II diabetes and obesity peptide therapies recently launched by Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) and the acceleration in approvals of oligonucleotide therapies make them a hot topic in the pharmaceutical world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
